#Omicron variant in India

[covid-safer-hotties]

Old News (Published Nov, 2022)

Also preserved on our archive

Pro-Tip: All covid-19 strains are capable of immune escape from both vaccination and acquired immunity from infection! Mask up to prevent the spread of covid and further mutation toward immune escape!

By Alice Park

New lab data suggest that vaccines and prior infections may not offer enough protection against several new COVID-19 variants cropping up in the U.S. and around the world.

Dr. David Ho, director of Columbia University’s Aaron Diamond AIDS Research Center (ADARC), and his team reported the results from a set of studies at an ADARC symposium. They showed how well some of the latest variants—BQ.1, BQ.1.1, XBB, and XBB.1, which were all derived from Omicron—are evading both vaccine-derived and infection-derived immunity.

These new variants all have mutations in the region that binds to cells and infects them, which means that they’re highly transmissible, as prior Omicron variants were. BQ.1 is growing steadily in France, according to the public database of SARS-CoV-2 variants GISAID. By mid-November, European health officials expect the variant to account for 50% of cases in Europe, and to become the dominant strain in that region by early 2023. XBB is growing quickly in Singapore and India. Both variants have spawned new strains that have each picked up an additional mutation to create BQ.1.1 and XBB.1. As of early November, BQ.1 and BQ.1.1, combined, now make up about 35% of new cases in the U.S.

Other studies have found similar drops in antibody protection against BQ.1 among vaccinated people. But Ho’s group conducted what is likely the most comprehensive look to date at BQ.1, BQ.1.1, XBB, and XBB.1, and how existing immunity—from the original mRNA vaccines, the new Omicron boosters, and natural infections—stands up to them. Scientists took blood sera from 88 people in five groups (below) and exposed it to the four variants in the lab. Here’s what they found:

Fully vaccinated and once-boosted people (three total shots of the original mRNA vaccines) had 37- and 55-fold lower neutralization against BQ.1 and BQ.1.1, respectively, than they did against the original SARS-CoV-2 virus, and about 70-fold lower neutralization against XBB and XBB.1. Fully vaccinated and twice-boosted people (four total shots of the original mRNA vaccines) had 43- and 81-fold lower neutralization against BQ.1 and BQ.1.1, respectively, than they did against the original virus, and 145- and 155-fold lower neutralization against XBB and XBB.1, respectively. Fully vaccinated and twice-boosted people (three shots of the original vaccine plus one Omicron booster) had 24- and 41-fold lower neutralization against BQ.1 and BQ.1.1, respectively, than they did against the original virus, and 66- and 85-fold lower neutralization against XBB and XBB.1, respectively. Fully vaccinated people who had received the original booster and who had been infected with BA.2 had 20- and 29-fold lower neutralization against BQ.1 and BQ.1.1, respectively, than they did against the original virus, and 103- and 135-fold lower neutralization against XBB and XBB.1, respectively. Fully vaccinated people who had received the original booster and who had been infected with BA.4 or BA.5 had 13- and 31-fold lower neutralization against BQ.1 and BQ.1.1, respectively, than they did against the original virus, and 86- and 96-fold lower neutralization against XBB and XBB.1, respectively.

The results show that people who had been infected with BA.2, BA.4, or BA.5 generally experienced the smallest drop in neutralizing antibody levels against against BQ.1 and BQ.1.1. But people who had three doses of the original vaccine and one Omicron booster produced only slightly better neutralizing antibody protection against XBB and XBB.1 than those who received three doses of the original vaccine. Public-health experts say that while vaccines may wane in efficacy against newer variants, they continue to protect people from severe COVID-19. There is early evidence that vaccine-induced immunity may also produce a broader range of virus-fighting antibodies over time.

Read More: BQ.1, BQ.1.1, BF.7, and XBB: Why New COVID-19 Variants Have Such Confusing Names

Still, these results are a reminder that vaccines and drug treatments need to evolve with the virus. “These new variants are extremely good at evading our antibodies and are very likely to compromise the efficacy of our vaccines,” says Ho. They may also dodge the available antibody-based treatments for COVID-19, he says. The National Institutes of Health’s COVID-19 Treatment Guidelines currently only include one monoclonal antibody therapy, bebtelovimab, because the virus has evaded all of the previously authorized antibody treatments. But in an October update, NIH scientists acknowledged that the “subvariants BQ.1 and BQ.1.1 are likely to be resistant to bebtelovimab.” The drug is therefore only recommended if people either can’t take the antiviral drugs Paxlovid or remdesivir, or if these medications aren’t available. The virus can evade these treatments as well, but they remain the first line of defense against severe SARS-CoV-2.

The good news is that in places where these variants are spreading, they do not seem to be linked to more severe COVID-19 disease—measured by hospitalizations and deaths—than other Omicron iterations. Still, public-health experts say a spike in infections could still strain health resources, especially as other respiratory infections, including influenza and RSV, also gain momentum. The combination of several circulating infectious diseases could mean more illness overall, and, in turn, more people who might experience severe disease and require intensive medical care.

The rise of BQ.1, BQ.1.1, XBB, and XBB.1 points to the fact that when it comes to immunity, the virus may always be one step ahead, especially with respect to vaccines. “I would start to make these vaccines, and start to test them in animals,” says Ho. Even if those efforts began now, it’s possible they may still lag behind the virus and the new mutations it continues to gain. That’s why researchers are working on developing vaccines that would be more universally applicable to a range of different coronaviruses, which could shorten the amount of time it takes to build up a vaccinated population’s immunity.

[darkmaga-returns]

By Nicolas Hulscher, MPH

Wang et al stipulated that, as global immunity from vaccination or prior infection becomes widespread, vaccine-resistant mutations are expected to become the dominant driver of SARS-CoV-2 evolution, enabling the virus to evade neutralizing antibodies and persist despite widespread immunity. Analyzing the evolutionary trajectories of vaccine-resistant mutations across more than 2.2 million SARS-CoV-2 genomes, they observed a strong correlation between the frequency of these mutations and vaccination rates in Europe and America:

A comprehensive research library that contains 63 peer-reviewed studies linking COVID-19 “vaccination” to the evolution of vaccine-resistant viral variants has just been published (Compiled by Dr. Steven Hatfill, MD, MMed, Erik Sass, et al). You can read it here:

The following collection of over 50 (n=63) peer-reviewed papers suggests the “vaccines” applied strong selective pressure to the fast-mutating SARS-CoV-2 virus, quickly giving rise to “vaccine”-resistant variants. It is noteworthy that variants emerged in temporal and geographic proximity to “vaccine” clinical trials or mass “vaccination”: 1. The Alpha variant was first identified in the county of Kent in southeast England in November 2020. Phase I/II clinical trials for AstraZeneca’s AZD1222 (ChAdOx1 nCoV-19) adenovector “vaccine” enrolled over 1,000 subjects in southern England in April 2020, and thousands more in the phase III trial, May-December 2020. 2. The Delta variant was first identified in Maharashtra state, India, in October 2020. Phase II/III clinical trials for the Covidshield adenovector “vaccine” based on AstraZeneca’s AZD1222 enrolled 1,600 subjects at 14 hospital centers, including eight in Maharashtra state, from July-October 2020. 3. The Omicron variant was first identified in Gauteng, South Africa, in November 2021, following an intense provincial “vaccination” campaign from August-October. On this note, public health officials have warned that “chasing variants” is likely futile:

[spooniestrong]

https://www.msn.com/en-us/health/other/who-charts-rapid-spread-of-new-jn1-covid-variant/ar-AA1lN6lZ

A sub-variant of the Omicron mutation of the Covid virus has been classified as a "variant of interest", by the World Health Organization, because of "its rapidly increasing spread".

JN.1 has been found in many countries around the world, including India, China and the United States.

[theculturedmarxist]

[...]

Cases aren't the only thing dropping either — so is surveillance of the virus. We're doing less testing and less sequencing of SARS-CoV-2 genetics.

Given all this, the question begs to be asked: Are we letting our guard down while waving the Mission Accomplished flag?

When asked if there is adequate surveillance for new variants happening, Dr. Margaret Harris, a spokesperson for the World Health Organization (WHO), flatly said no.

"Current trends in reported COVID-19 cases are underestimates of the true number of global infections and reinfections as shown by prevalence surveys," Harris told Salon in an email. "This is partly due to the reduction in testing and delays in reporting in many countries. Reduction in testing means a reduction in genetic sequencing, as you need to find the virus first in order to sequence it."

"We continually call on member states to maintain strong testing and sequencing in order to identify new variants but also to understand the level of SARS-CoV-2 transmission going on in their populations," Harris continued. "This virus remains unstable — it has not settled into a predictable pattern, which means surveillance systems need to be sensitive to pick up the early signs of another surge."

XBB.1.5, nicknamed by some as "Kraken," is thus far the dominant variant for most of 2023, with estimated cases of Kraken exceeding 70 percent since the week of Feb 11. It has far eclipsed the BQ.1 and BQ.1.1 variants. Meanwhile BA.2 and BA.5, the two variants that dominated case counts for most of 2022, have all but disappeared.

According to the latest CDC variant tracking data, the only other variants really circulating in the U.S. are XBB.1.5's offspring: XBB.1.9 and XBB.1.5.1. Meanwhile, XBB.1.16 is spreading rapidly in India and could eventually make its way to North America. Notably, XBB was first detected in Singapore before its offspring made the jump across the Pacific, though XBB.1.5 was first detected in the U.S. and likely originated in the Northeast.

All these names may sound like gobbledygook to most non-experts — and there is a reason it's so confusing. When variants of the virus mutated and evolved into new strains with significant advantages over old lineages, the WHO began giving these "variants of concern" names from the Greek alphabet. Hence, variants like delta and gamma made headlines when they emerged and began to spread — but the WHO has yet to assign any variants a new Greek name since omicron surged in late 2021. Instead, we have this alphabet soup of named variants, all of which are technically different sub-strains of omicron.

Even a minor variation in a virus' genetics can equate to a huge difference in how well immunity from vaccines and previous infections can stop them. If the virus evolves some kind of advantage — as viruses are prone to do and just as SARS-CoV-2 has done many times throughout the pandemic — another surge is not out of the question.

In mid-March, the WHO updated their definition of what makes COVID variants threatening and currently classifies XBB.1.5 as a "variant of interest," which means it is seen as less threatening than previous variants of concern.

Nonetheless, some virologists have argued that XBB and its close relatives are so genetically different from the very first strain of SARS-CoV-2 that it should technically be renamed a new virus, SARS-CoV-3.

"XBB.1.5 does show a growth advantage and a higher immune escape capacity, but evidence from multiple countries does not suggest that XBB and XBB.1.5 are associated with increased severity or mortality," Harris said. "In countries where the variant has driven an increase in cases, the waves are significantly smaller in scale compared to previous waves."

That's good news, but as the virus bounces between hemispheres, it may gain new mutations that allow it to infect more effectively or evade immunity. Some of our treatments, but not all, have stopped working against XBB strains. Monoclonal antibodies don't stop it, but antiviral drugs like Paxlovid and bivalent booster vaccines are still very effective.

But the combined lack of public interest in the pandemic, exemplified in victory marches from political leadership, has led to a shrinking pool of data on COVID as there is less funding afforded to tracking and research. As we've seen in previous surges, the situation can change without warning. The situation is made worse by wild animals that harbor COVID, a viral reservoir that could spill back to humanity if given the opportunity.

"The level of genomic surveillance has been dropping off, and there are also indications that funding for wastewater monitoring will be ending in some places," Dr. T. Ryan Gregory, an evolutionary and genome biologist at the University of Guelph in Canada, told Salon in an email. "We have far less information than we used to, which hampers the ability to detect and track new variants. It's also worth noting that India and China include about one-third of the world's population, and we have very little information on variants there."

While overall trends are down, many people would be especially vulnerable to a COVID infection right now, according to Dr. Rajendram Rajnarayanan, an assistant dean of research and associate professor at the New York Institute of Technology campus in Jonesboro, Arkansas.

"Very few of us have had the bivalent booster, so in terms of protection, we are kind of vulnerable," Rajnarayanan told Salon. He noted that COVID is still a serious, life-threatening disease for immunocompromised people and those over 70. Most people who got bivalent booster shots — if they did so at all — received the jab in the fall. By now, that immunity has likely waned and there hasn't been much communication about when or if a new booster will come out later this year. According to NPR, the Food and Drug Administration has said it will allow some people over the age of 65 to get a second bivalent booster, but it hasn't been officially announced yet.

So while infections are trending downward, immunity is as well. In the past, major gaps in immunity have been followed by major surges, such as with delta and omicron.

"When there is a big pause, and some new variant comes, we are not really protected. But when there are repeated waves, the previous wave usually protects the next wave." Rajnarayanan said. "Every time the variant goes down, something goes up later on. Just the gap between the two peaks has changed."

Despite the unpredictability of SARS-CoV-2, the strategy for fighting it hasn't changed. Masking in public, improving indoor ventilation, testing when appropriate, staying home when sick and keeping up with vaccines when possible are good strategies for keeping the virus at bay. But overall, it's not enough to say the emergency is over. We need to be strategic and keep a close eye on the evolution of COVID as well.

"People have changed, our approaches have changed, and we don't need any modern approaches to defeat this virus," Rajnarayanan said. "We know how to do this . . .  we have to do it collectively. That's all there is to it."

[noneofthisisreal]

“Itchy” conjunctivitis—or pinkeye—without pus, but with “sticky eyes”

[indian-business-times]

Impact of Omicron on India’s Hospitality and Tourism Industry | Dr. GVK Reddy

Dr. GVK Reddy provides valuable insights on how the Omicron variant is affecting India’s hospitality and tourism sectors. In the wake of the ongoing COVID-19 pandemic, the arrival of Omicron has exacerbated the challenges faced by businesses in these industries. Despite efforts to recover from previous losses, the new variant has caused stock prices in the hospitality, travel services, and entertainment industries to plummet, leading to concerns about a potential new lockdown in India.

The renewed fears of restrictions have sparked a sense of dread among investors, and many are uncertain about the future. The situation has left a massive impact on India's economy, especially in sectors like tourism, aviation, and hospitality that have been struggling to regain momentum. As a result, businesses are witnessing declining stocks and rising anxiety about their financial stability.

In this critical period, Dr. GVK Reddy shares expert opinions on how the Indian hospitality and tourism industries can navigate the current crisis. For more industry insights, visit Indian Business Times for regular updates on economic shifts affecting key sectors.

[glorioustidalwavedefendor]

Also, it looks like only the Saliva tests are accurate and they are over a hundret bucks ... like the cheapest clocks in at aroun 130$

[brookstonalmanac]

Events 11.26 (after 1950)

1950 – Korean War: Communist Chinese troops launch a massive counterattack (Battle of the Ch'ongch'on River and Battle of Chosin Reservoir) against United Nations and South Korean forces. 1965 – France launches Astérix, becoming the third nation to put an object in orbit using its own booster. 1968 – Vietnam War: United States Air Force helicopter pilot James P. Fleming rescues an Army Special Forces unit pinned down by Viet Cong fire. He is later awarded the Medal of Honor. 1970 – In Basse-Terre, Guadeloupe, 38 millimetres (1.5 in) of rain fall in a minute, the heaviest rainfall ever recorded. 1977 – An unidentified hijacker named Vrillon, claiming to be the representative of the "Ashtar Galactic Command", takes over Britain's Southern Television for six minutes, starting at 5:12 pm. 1979 – Pakistan International Airlines Flight 740 crashes near Taif in Mecca Province, Saudi Arabia, killing all 156 people on board. 1983 – Brink's-Mat robbery: In London, 6,800 gold bars worth nearly £26 million are stolen from the Brink's-Mat vault at Heathrow Airport. 1986 – Iran–Contra affair: U.S. President Ronald Reagan announces the members of what will become known as the Tower Commission. 1986 – The trial of John Demjanjuk, accused of committing war crimes as a guard at the Nazi Treblinka extermination camp, starts in Jerusalem. 1991 – National Assembly of Azerbaijan abolishes the autonomous status of Nagorno-Karabakh Autonomous Oblast of Azerbaijan and renames several cities with Azeri names. 1998 – Tony Blair becomes the first Prime Minister of the United Kingdom to address the Oireachtas, the parliament of the Republic of Ireland. 1998 – The Khanna rail disaster takes 212 lives in Khanna, Ludhiana, India. 1999 – The 7.5 Mw  Ambrym earthquake shakes Vanuatu and a destructive tsunami follows. Ten people were killed and forty were injured. 2000 – George W. Bush is certified the winner of Florida's electoral votes by Katherine Harris, going on to win the United States presidential election, despite losing in the national popular vote. 2003 – The Concorde makes its final flight, over Bristol, England. 2004 – Ruzhou School massacre: A man stabs and kills eight people and seriously wounds another four in a school dormitory in Ruzhou, China. 2004 – The last Poʻouli (Black-faced honeycreeper) dies of avian malaria in the Maui Bird Conservation Center in Olinda, Hawaii, before it could breed, making the species in all probability extinct. 2008 – Mumbai attacks, a series of terrorist attacks killing approximately 175 citizens by 10 members of Lashkar-e-Taiba, a Pakistan based extremist Islamist terrorist organisation. 2008 – The ocean liner Queen Elizabeth 2, now out of service, docks in Dubai. 2011 – NATO attack in Pakistan: NATO forces in Afghanistan attack a Pakistani check post in a friendly fire incident, killing 24 soldiers and wounding 13 others. 2011 – The Mars Science Laboratory launches to Mars with the Curiosity Rover. 2018 – The robotic probe Insight lands on Elysium Planitia, Mars. 2019 – A magnitude 6.4 earthquake strikes western Albania leaving at least 52 people dead and over 1,000 injured. This was the world's deadliest earthquake of 2019, and the deadliest to strike the country in 99 years. 2021 – COVID-19 pandemic: The World Health Organization identifies the SARS-CoV-2 Omicron variant.

[gendronrecherche]

KP.2 COVID Variant Now Dominant in India

The KP.2 COVID variant, an Omicron subvariant with increased transmissibility, has overtaken other strains in India. http://dlvr.it/TBT2pm

[covid-safer-hotties]

Why Biden’s premature COVID ending could help it surge - Published Sept 23, 2022

Two years out from the publication of this article, and we can really see how true these warnings were. Why does the mainstream media and DNC refuse to do anything about forever covid?

This week, President Biden said what millions of Americans have been hoping to hear since the spring of 2020: “The pandemic is over.”

I understand the impulse to close the book and move on. But I am deeply concerned that this declaration is not only premature but also dangerous.

The SARS-CoV-2 virus has shown us, again and again, the danger of hubris. Think of the lethal impact of the omicron virus last winter, just when we were so grateful that the delta wave had ebbed. Think of the deadly surges this summer, just when we were planning our long-delayed vacations. This is a virus that has humbled us too often. We must approach it with humility.

This declaration has many damaging effects: As others have noted, it will now be even harder to persuade Americans to get the new bivalent boosters. It’ll be tougher to persuade Congress to fund essential COVID responses. And it will be nearly impossible for local officials to impose new indoor mask requirements should another surge arrive.

To be sure, Biden did acknowledge in his “60 Minutes” interview that “we still have a problem with COVID” and added that “we’re still doing a lot of work on it.” But he sandwiched that message between two flat declarations that the pandemic is over. Those are the soundbites that have reverberated most loudly, and they are decidedly unhelpful.

Dr. Tom Frieden, former director of the Centers for Disease Control and Prevention, has spoken often about how the U.S. has lurched from a cycle of panic to neglect when it comes to public health. Many of us in the field had hoped that the COVID-19 pandemic would break that cycle — a sliver of silver lining amid all the grief.

We had hoped that policymakers and voters alike would understand how essential it is to upgrade our data infrastructure, stockpile essential medicine and equipment, invest in preventive care for vulnerable populations, restructure our emergency response agencies and support an infusion of public health workers at the local and state levels. Surely, COVID would be the spur needed to finally bump U.S. spending on public health to more than 3 cents on the health care dollar.

By declaring the pandemic over when we are still very much in the thick of the fight, President Biden is undercutting that message.

Let’s look at where we are right now. The U.S. is still reporting close to 60,000 cases and 400 deaths each day. Millions are struggling with long COVID; by some estimates, this often debilitating condition is keeping 4 million adults out of work. Those at work may have less flexibility: Major companies are ending work-from-home policies and Starbucks announced this week that it will no longer give employees paid time off to isolate or get vaccinated. Biden’s remarks will only accelerate that trend.

Meanwhile, only 67 percent of Americans are vaccinated and only half of them have been boosted. While many of the remaining have some immunity from infection, the death toll makes clear that large swaths of the population remain highly vulnerable. And of course, new variants continue to emerge; right now, all eyes are on BA.2.75.2, a mutation of the omicron variant that is notably better at evading antibodies acquired from vaccination or prior infection and is spreading rapidly in India.

Declaring the pandemic over at this stage is tantamount to accepting all this misery as background noise.

And if we accept the status quo as background noise — rather than the urgent and immediate threat it represents — it’s nearly impossible to make the case that we need to do more as a society to protect the vulnerable, respond to surges, or prepare for future crises.

The Biden administration has made significant strides on COVID. It made tests, vaccines and treatments widely available across the country, which improved outcomes and saved lives. The vast majority of Americans feel we’re in a better place than at this time last year and many have returned, at least in large part, to normal activities.

It is an appropriate moment for our leaders to turn the page away from our wartime footing and begin a sober discussion about the next steps: the risks that remain, the importance of responding quickly to local surges, the value of supporting the Global South in building their own vaccine infrastructure — and the critical need to rebuild the battered and woefully outdated public health infrastructure in the U.S.

It is not the moment to declare victory.

John M. Barry, author of “The Great Influenza: The Story of the Deadliest Pandemic in History” has a stark warning from history. He writes that the world had largely moved on from the 1918 influenza pandemic when a fourth wave struck in 1920. By then, the U.S. had plenty of natural immunity from prior infection. Still, the virus spread ruthlessly. Public officials failed to respond. They, like the public, wanted the pandemic to be over — so the virus rolled on unchecked. In some cities, the death toll in 1920 exceeded the toll of the huge second wave.

We should not make the same mistake now. With humility as our watchword, we can move to the next chapter without closing the book. That is the way forward.

Michelle A. Williams is dean of the faculty of the Harvard T.H. Chan School of Public Health.

[toneophealth]

COVID-19 Variants Overview: Is JN 1 the Most Dangerous? Full List Till 2023

Since the onset of the COVID-19 pandemic, numerous iterations of the SARS-CoV-2 virus, the causative agent behind the illness, have surfaced. Notable among these are variants such as Alpha, Beta, Delta, and Omicron. Global scientific endeavors have remained vigilant in tracking the evolutionary shifts within the COVID-19 virus. Their investigations stand crucial in comprehending whether specific strains of COVID-19 exhibit heightened transmissibility, potential health implications, and the efficacy of existing vaccines against them.

Over the span of the past three years, the World Health Organization has cataloged nine variants as actively circulating. While over 50 variants have been documented, some have ceased their spread.

Now, attention is drawn to the emergence of the new sub-variant of COVID-19, JN 1. Concerns arise: should this new iteration prompt worry? And if so, what level of threat does it pose? The sudden surge of the JN 1 COVID-19 sub-variant in India and across regions has instilled widespread apprehension. Delve into this comprehensive guide to acquire essential insights regarding JN 1 and the spectrum of COVID variants.

Read More:

[nepalniceties]

WHO flags Omicron Sub-Variant JN.1 as "Variant of Interest" due to rapid spread

The World Health Organization (WHO) has identified a sub-variant of the Omicron strain, named JN.1, as a “variant of interest” owing to its swift and widespread transmission. JN.1 has surfaced in numerous countries globally, including India, China, the UK, and the United States. Despite its escalating spread, the WHO reassures the public that the risk remains low, and existing vaccines continue…

[werindialive]

21 cases of Covid-19 subvariant JN. 1 detected in India, authorities on high alert

With the fresh cases of coronavirus subvariant JN.1 emerging in India, Indian authorities have been on high alert. The subvariant JN. 1 is being investigated by the scientific community as the authorities work on curbing its spread already. As per NITI Aayog member (health) Dr V K Paul, as of now, 21 cases of COVID-19 JN.1 sub-variant have been detected in the country. The Indian Council of Medical Research (ICMR) is focused on the genome sequencing of the variant.

Out of the 21 cases, 19 cases have been detected in Goa while Kerala and Maharashtra have recorded one each.

First found in late 2023, the JN.1 (BA.2.86.1.1) variant of COVID-19 is a descendant of the BA.2.86 lineage (Pirola) of SARS-CoV-2. The BA.2.86 lineage (Pirola) first emerged in August 2023 and showed more than 30 mutations in the spike (5) protein unlike the SARS-CoV-2 Omicron XBB lineages. The mutations make the variant highly risky with a high potential for immune evasion.

The JN.1 subvariant has been classified as a variant of interest by the World Health Organization.

Head of Pulmonary Medicine at Safdarjung Hospital, Dr. Rohit Kumar said, “COVID is an RNA virus that changes its form from time to time, and new variants of it emerge. And now a new variant has emerged, which has been named JN.1. However, not a single case has come to light in the capital, Delhi yet.”

"We are on alert, keeping an eye on the Corona cases. Testing of patients is also being done, and the patients who are coming positive are also being sent for genome sequencing. So that new variants can also be detected, but till now no case of new variants has been reported in Delhi," Dr Kumar said.

"If there is a sore throat, cough, cold, chest pain, or difficulty breathing, consult the doctor immediately. Especially those already suffering from respiratory diseases and asthma patients need to take special care. The doctor mentioned that during this season, individuals with serious diseases should be more careful, as those dying due to Covid often have pre-existing serious conditions such as heart disease and diabetes," he added.

For more COVID-19 news India in Hindi, subscribe to our newsletter.